Risperidone for treatment-resistant schizophrenia: Initial clinical experience in a state hospital
- Peter F. Buckley(corresponding author),
- Karl Donenwirth,
- Kenneth E. Bayer,
- Christine Lys,
- Zafar Ibrahim,
- S. Charles Schulz
- ,
- Northcoast Behavioral Healthcare System,
- Case Western Reserve University
Scholary Output:
Contribution to journal
Review article
Research
Peer-reviewAbstract
<p>Objective: To examine the efficacy of risperidone, a new antipsychotic with combined serotonergic-dopaminergic antagonism, in patients with treatment-resistant schizophrenia in state facilities. Methods: Brief Psychiatric Rating Scale (BPRS) evaluations were performed on 21 patients with schizophrenia who had received risperidone therapy for 10 weeks in a state facility. Results: Five patients showed a 20% reduction on their pretreatment BPRS score. A corresponding number of patients showed an increased BPRS score during treatment, and the remainder attained a modest reduction (2-17%) in symptoms on the BPRS. Conclusions: Although risperidone was an effective antipsychotic for patients with chronic treatment-resistant schizophrenia, only a subgroup of these patients achieved substantial clinical improvement over a 10-week period.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Review article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 271-275 (5 pages)Journal (Volume, Issue Number)
Journal of Pharmacy Technology (Volume 12, Issue 6)Publication milestones
- Published - 1996
Publication status
Published - 1996
ISSN
8755-1225Publication IDs
- Scopus: 0030446358
Publication metrics
Metrics
SciVal
citations
5
SciVal
FWCI
1.11
SciVal
Author count
6
SciVal
Paper percentile
49
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Citation count
6
Captures
3
